PHIO

PhioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$2.00

+78.6% vs current

Most likely

Base case

45%

Probability

Target price

$1.15

+2.7% vs current

B-

Bear case

30%

Probability

Target price

$0.45

-59.8% vs current

AI sentiment snapshot

Latest data as of 2026-05-16

AI commentary

This was a T+3 earnings follow-up, but the company-source earnings release actually arrived on May 7, 2026 via the 8-K and attached press release, while the queue label referenced May 13, 2026 [#8-K-2026-05-07]. The new evidence is directionally better than the prior baseline because management moved PH-762 from trial enrollment/tolerability monitoring to completed dose escalation, targeted Q2 FDA interaction, and identified toxicology and cGMP supply work, but conviction should stay moderate because immediate post-print analyst revisions were not confirmed and trustworthy consensus-surprise data were unavailable. With the anchor price still only $1.07 on May 15, 2026, the market is still treating PHIO as a highly speculative, financing-sensitive microcap rather than fully capitalizing the development update.

RankAlpha Sentiment Codex - 2026-05-16

Open post-earnings memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-06-30eventQ2 2026 FDA interaction on PH-762 next-step study designHigh impact

Phio said the Phase 1b clinical phase for PH-762 is complete, final data are being analyzed, and an FDA submission to seek guidance on next-step clinical study design is targeted for Q2 2026; this is the clearest near-term post-earnings inflection from the May 7, 2026 update [#PR-2026-05-07] [#8-K-2026-05-07] [#10-Q-2026-05-07].

2026-08-31catalystPH-762 final data digestion and advancement packageHigh impact

Management disclosed favorable safety/pathology framing, 22 enrolled patients, and a reported 65% overall response rate in cutaneous squamous cell carcinoma while noting final study data are still under formal analysis; confirmation of durability, cohort detail, and the resulting development path could materially re-rate or de-rate the single-asset story [#PR-2026-05-07] [#10-Q-2026-05-07].

2027-03-31catalystIND-enabling toxicology and cGMP supply package for PH-762High impact

The 10-Q says Phio entered a December 2025 development-services agreement for a nonclinical toxicology study required before a registration-purpose human clinical trial and a March 2026 cGMP drug-product manufacturing services agreement for clinical supplies; successful execution would be a distinct long-horizon program catalyst beyond the initial FDA interface [#10-Q-2026-05-07] [#PR-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-16 • Updated nightlySource: Internal modelMethodology